EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator

Russell Griffin iD, Rebecca Arend

Current Oncology · 2025

DOI: 10.3390/curroncol32070401 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Current Oncology, 2025. Verfasst von Russell Griffin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Meningioma, Medroxyprogesterone Acetate, Meningeal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control. The current matched case–control study utilized a bootstrapped sampling design, matching 241 CM cases with controls (i.e., women diagnosed with non-meningioma brain, breast, or skin tumor, one control per type for three total) on age ± 5 years and diagnosis date ± 3 months. Conditional logistic regression was used to estimate odds ratios (ORs) compared with an active (norethindrone or levonorgestrel) and non-active control group. Exposure to dMPA at any time point was not associated with the diagnosis of cerebral meningioma (OR 1.75, 95% CI 0.81–4.95). Exposure to dMPA within a year of diagnosis was associated with the diagnosis of CM compared to both an active control (OR 3.38, 95% CI 1.13–9.70) and a non-active control (OR 6.90, 95% CI 2.31–17.58). This association was also present for those who were exposed within two years prior when compared to a non-active control (OR 3.54, 95% CI 1.50–11.88) but not an active control. Combined with the prior literature, the current results suggest that future research is warranted to understand this association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMedroxyprogesterone AcetateMeningeal NeoplasmsHumansCase-Control StudiesFemaleMiddle AgedAdultAged

Stichwörter der Autor:innen

cerebrallevonorgestrelmedroxyprogesteronemeningiomanorethindrone

Substanzen

Medroxyprogesterone Acetate

Autor:innen und Institutionen

  • Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Department of Obstetrics and Gynecology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

ORCID-Profile: Russell Griffin

Zitieren

APA

Griffin, R., & Arend, R. (2025). A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator. Current Oncology. https://doi.org/10.3390/curroncol32070401

Vancouver

Griffin R, Arend R. A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator. Current Oncology. 2025. doi:10.3390/curroncol32070401

BibTeX
@article{Griffin2025,
  author = {Griffin, Russell and Arend, Rebecca},
  title = {A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32070401}
}
Kostenlos starten →